A PHASE 2 STUDY OF REVUMENIB (SNDX-5613) IN COMBINATION WITH
CHEMOTHERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY KMT2A-REARRANGED
INFANT LEUKEMIA
- Registry ID
- AALL2121
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- CHILDRENS ONCOLOGY GROUP
- Start date
- 2025-05-16
- Last update
- 2025-02-06
Conditions
Related clinical trials
- A PHASE 1 TRIAL OF THE MENIN INHIBITOR ZIFTOMENIB IN COMBINATION WITH CHEMOTHERAPY FOR CHILDREN WITH RELAPSED/REFRACTORY KMT2A-REARRANGED, NUP98-REARRANGED, OR NPM1-MUTANT ACUTE LEUKEMIA
- A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ADMINISTRATION OF SUBCUTANEOUS BLINATUMOMAB FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B ALL
- AN EXTENSION STUDY OF VENETOCLAX FOR SUBJECTS WHO HAVE COMPLETED A PRIOR VENETOCLAX CLINICAL TRIAL
- IDENTIFICATION AND EVALUATION OF PATIENTS AT RISK OF DEVELOPING CARDIOTOXICITY AFTER RECEIVING CHEMOTHERAPY FOR BREAST CANCER, LEUKEMIA OR LYMPHOMA
- A PHASE 3 RQANDOMIZE TRIAL OF INOTUZUMAB OZOGAMICIN (IND#: 133494, NSC#: 772518) FOR NEWLY DIAGNOSED HIGH-RISK B-ALL; RISK-ADAPTED POST-INDUCTION THERAPY FOR HIGH-RISK B-ALL, MIXED PHENOTYPE ACUTE LEUKEMIA, AND DISSEMINATED B-LLY
- LAROTRECTINIB (LOXO-101, NSC# 788607, IND# 141824) FOR PREVIOUSLY UNTREATED TRK FUSION PEDIATRIC SOLID TUMORS AND TRK FUSION RELAPSED PEDIATRIC ACUTE LEUKEMIAS
View on source registry